Brought to you by 
Lilly calls on Adimab in antibody discovery alliance; expanded
18 Jul 2017
Executive Summary
Eli Lilly & Co. has received an exclusive option to research antibodies identified by monoclonal antibody developer Adimab Inc. Lilly will select two targets. Adimab disclosed the agreement concurrent with separate antibody discovery deals with Genentech and Human Genome Sciences.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lilly calls on Adimab in antibody discovery alliance; expanded
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice